MIRM: Mirum Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for MIRM
Across the 15 sessions after earlier MIRM headlines, the stock closed higher 10 times and lower 5 times, with a median move of 1.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MIRM | SPY |
|---|---|---|---|
| Jan 26, 2026 | Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease | +2.8% | +0.5% |
| Jan 13, 2026 | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +1.1% | -0.2% |
| Jan 12, 2026 | Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum | +3.4% | +0.2% |
| Jan 9, 2026 | Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals | +6.1% | +0.7% |
| Jan 8, 2026 | Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference | -0.5% | -0.0% |
| Dec 19, 2025 | Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX | +10.6% | +0.6% |
Quantisnow market dataNASDAQ
MIRM
Mirum Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2019
Get push alerts for MIRM
Full MIRM profile on Quantisnow Follow MIRM and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time